Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
In a significant stride towards advancing cancer research and drug development, the European Organisation for Research and Treatment of Cancer (EORTC) has joined forces with the European Medicines Agency (EMA) in a groundbreaking collaboration. This strategic partnership aims to foster innovation, streamline processes, and accelerate the translation of scientific discoveries into effective cancer treatments.
The first half of 2024 will see an extraordinary series of workshops where EORTC and EMA will work hand in hand to address the many challenges of clinical research: from ultra-rare cancers to quality of life and treatment optimisation.
By fostering synergies between academic research and regulatory processes, this partnership aims to accelerate the delivery of new and effective cancer treatments to patients across the European Union.
Denis Lacombe, EORTC CEO expressed immense enthusiasm about this series of workshops: “This unique collaboration is a remarkable testament to the shared commitment of EORTC and EMA to advancing cancer research. By combining our expertise, we aim to overcome hurdles and accelerate the development of innovative and effective therapies for the benefit of patients.”
The collaborative efforts of EORTC and EMA are expected to pave the way for a more harmonised and efficient landscape in cancer research and drug development, offering renewed hope for patients and further establishing Europe as a leader in the global fight against cancer.
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023
EORTC & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer
19 Oct 2023